| BRL 50481PDE7 inhibitor,potent and selective |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
BRL 50481 Dilution Calculator
calculate
BRL 50481 Molarity Calculator
calculate
| Cas No. | 433695-36-4 | SDF | Download SDF |
| Chemical Name | N,N,2-trimethyl-5-nitrobenzenesulfonamide | ||
| Canonical SMILES | CC1=C(S(N(C)C)(=O)=O)C=C(N(=O)=O)C=C1 | ||
| Formula | C9H12N2O4S | M.Wt | 244.27 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
BRL 50481 is a selective inhibitor of phosphodiesterase (PDE) 7. At substrate concentrations of 50 nM and 1 ?M, the hydrolysis of cAMP by hrPDE7A1 was inhibited by BRL 50481 with IC50 values of 0.26 and 2.4 ?M, respectively [1]. BRL 50481 is a selective and potent inhibitor of human recombinant PDE7A with an IC50 value of 26 nM [2].
PDE7 is of a high affinity as a cAMP-specific PDE. PDE7 could be a good treatment target for T cell related diseases, airway diseases or central nervous system (CNS) disorders [3].
At 1 ?M and 50 nM cAMP, BRL 50481 was a selective inhibitor of hrPDE7A1, with 416 and 1884 times less potencies against PDE3, and 38 and 238 times less potencies against hrPDE4A4, respectively. BRL 50481 did not significantly inhibit PDE1C, PDE1B, PDE5 and PDE2 at concentrations below 100 ?M. BRL 50481 showed a competitive inhibition potency against hrPDE7A1 with a Ki value of 180±10 nM. But in MOLT-4 T cells, BRL 50481 increased the cAMP content with an EC50 >> 100 ?M. The EC80 value of rolipram is about 10 ?M. When the effect of BRL 50481 at concentrations of 10–300 ?M on cAMP mass was examined in the presence of rolipram at a submaximal concentration, the mean concentration-response curve of BRL 50481 was displaced upwards of a significantly greater magnitude, compared to the sum of the cAMP response affected by BRL 50481 and rolipram alone [1].
Compared to treatment with A-350619 or BRL 50481 alone, the combination of methylene blue and BRL 50481 significantly delayed the onset of action in received mice for jerky movements and convulsion. The combination of methylene blue and exogenously administered BRL 50481 (2 mg/kg, i.p.) significantly had an anti-convulsant activity [4].
References: [1]. Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol, 2004, 66(6):1679-89.[2]. Gil C, Campillo NE, Perez DI, et al. PDE7 inhibitors as new drugs for neurological and infl ammatory disorders. Expert Opin Ther Patents, 2008, 18(10):1127-1139.[3]. Castro A, Jerez MJ, Gil C, et al. CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem, 2008, 43(7):1349-59.[4]. Nandhakumar J, Ernest V and Tyagi MG. Evaluation of Seizure Activity After Phospho-diesterase Inhibition (BRL 50481) with Guanylate Cyclase Activation (A-350619) and Inhibition (Methylene blue) in Animal Models of Epilepsy. J Neurol Neurophysiol, 2011, 2:110.
